A. Mark Richards
Arthur Mark Richards (born 1 May 1955) is a New Zealand physician, academic and medical researcher. He is a professor of cardiology and director of the Cardiovascular Research Institute at the National University of Singapore, and a professor of medicine and founder of the Christchurch Heart Institute at the University of Otago, Christchurch, New Zealand, where he holds the National Heart Foundation (NZ) Chair of Cardiovascular Studies.Richards has written over 850 peer-reviewed journal articles, and has over 25 patents in the field of cardiovascular biomarkers. His research revolves around integrated cardiovascular translational research incorporating clinical applied research, molecular biology, cardiovascular peptide biochemistry, genetics and preclinical physiology, with a particular focus upon discovery and application of biomarkers in cardiovascular disease.
Richards is a fellow of the Royal Australasian College Physicians (FRACP), Royal College of Physicians (FRCP) and Royal Society of New Zealand (FRSNZ), and the Council for High Blood Pressure Research, American Heart Association. Provided by Wikipedia
Showing 1 - 6 results of 6 for search 'A. Mark Richards', query time: 0.01s
Refine Results
-
1
-
2
Lower NT‐proBNP plasma concentrations in Pacific peoples with heart failure by Andree G. Pearson, John F. Pearson, Lynley K. Lewis, Allamanda Fa'atoese, Katrina K. Poppe, Chris Pemberton, Gerry Devlin, Mayanna Lund, A. Mark Richards, Richard Troughton, Robert N. Doughty
Published 2025-08-01Get full text
Article -
3
Left Atrial Myocardial Mechanics: Association With Cognitive Dysfunction, Cerebrovascular Disease, and Circulating Biomarkers by Eugene S. J. Tan, Saima Hilal, Siew Pang Chan, Ming Ann Sim, Mitchell K. P. Lai, Joyce Chong, Caroline Robert, Hazliza Hazli, Lingli Gong, Josephine Lunaria Berboso, Narayanaswamy Venketasubramanian, Boon‐Yeow Tan, A. Mark Richards, Christopher Chen, Lieng‐Hsi Ling
Published 2025-04-01Get full text
Article -
4
Effects of sacubitril/valsartan on hypertensive heart disease: the REVERSE-LVH randomized phase 2 trial by Vivian Lee, Mayank Dalakoti, Qishi Zheng, Desiree-Faye Toh, Redha Boubertakh, Jennifer A. Bryant, Tar-Choon Aw, Chi-Hang Lee, A. Mark Richards, Javed Butler, Javier Díez, Roger Foo, Stuart A. Cook, Carolyn SP Lam, Thu-Thao Le, Calvin WL Chin
Published 2025-07-01Get full text
Article -
5
Proteomic Correlates and Prognostic Significance of Kidney Injury in Heart Failure With Preserved Ejection Fraction by Oday Salman, Lei Zhao, Jordana B. Cohen, Marie Joe Dib, Joe David Azzo, Sushrima Gan, A. Mark Richards, Bianca Pourmussa, Rob Doughty, Ali Javaheri, Douglas L. Mann, Ernst Rietzschel, Manyun Zhao, Zhaoqing Wang, Christina Ebert, Vanessa van Empel, Karl Kammerhoff, Joseph Maranville, Joseph Gogain, Jaclyn Dennis, Peter H. Schafer, Dietmar Seiffert, David A. Gordon, Francisco Ramirez‐Valle, Thomas P. Cappola, Julio A. Chirinos
Published 2024-09-01Get full text
Article -
6
Immunotherapy targeting isoDGR‐protein damage extends lifespan in a mouse model of protein deamidation by Pazhanichamy Kalailingam, Khalilatul‐Hanisah Mohd‐Kahliab, SoFong Cam Ngan, Ranjith Iyappan, Evelin Melekh, Tian Lu, Gan Wei Zien, Bhargy Sharma, Tiannan Guo, Adam J MacNeil, Rebecca EK MacPherson, Evangelia Litsa Tsiani, Deborah D O'Leary, Kah Leong Lim, I Hsin Su, Yong‐Gui Gao, A Mark Richards, Raj N Kalaria, Christopher P Chen, Neil E McCarthy, Siu Kwan Sze
Published 2023-11-01Get full text
Article